Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alpha Tau MedicalDRTSW 27 14-Day RSI is 21.76 as of Sep. 09, 2026. GuruFocus rates DRTSW with a GF Score™ of 27/100. The stock has 3 warning signs investors should review. Among 1,420 Biotechnology companies, Alpha Tau Medical ranks worse than 84.01% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
Alpha Tau Medical (NAS:DRTSW) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Alpha Tau Medical 14-Day RSI Related Terms
DRTSW vs OMER, ORIC, VOR: 14-Day RSI Comparison
For the Biotechnology subindustry, Alpha Tau Medical's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpha Tau Medical 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alpha Tau Medical's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Alpha Tau Medical's 14-Day RSI falls into.
Alpha Tau Medical (NAS:DRTSW) 14-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alpha Tau Medical (DRTSW) has a 14-Day RSI of 21.76 as of Sep. 09, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Alpha Tau Medical and its competitors. According to the industry distribution chart, Alpha Tau Medical ranks #1193 out of 1420 companies in the Biotechnology industry, placing it in the top 84%.
Is Alpha Tau Medical's 14-Day RSI too high?
Alpha Tau Medical's current 14-Day RSI is 21.76. The Biotechnology industry median 14-Day RSI is 48.29. Alpha Tau Medical's value of 21.76 is 54.9% below this industry median. Based on the distribution chart, Alpha Tau Medical ranks #1193 out of 1420 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alpha Tau Medical has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Alpha Tau Medical's 14-Day RSI compare to OMER and ORIC?
According to the Biotechnology industry distribution chart, Alpha Tau Medical ranks #1193 out of 1420 companies for 14-Day RSI. This places Alpha Tau Medical in the lower half of its industry. The industry median 14-Day RSI is 48.29. Alpha Tau Medical's value of 21.76 is 54.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 48.29, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alpha Tau Medical's current 14-Day RSI of 21.76 is 54.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Alpha Tau Medical and its competitors. For the Biotechnology industry, the median 14-Day RSI is 48.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alpha Tau Medical's current 14-Day RSI is 21.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Tau Medical stock overvalued right now?
Alpha Tau Medical (DRTSW) has a current 14-Day RSI of 21.76. The current 14-Day RSI is 21.76 and 54.9% below the Biotechnology industry median of 48.29. Alpha Tau Medical's overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Alpha Tau Medical (DRTSW), the current 14-Day RSI is 21.76 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
27GF Score
Get the complete analysis for DRTSW
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DRTSW has been successfully added to your 
